Artal Group S.A. Ventyx Biosciences, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$29.8 - $40.3 $97,744 - $132,184	-3,280 Reduced 0.8%	405,239 $14.1 Million
Q2 2023 Aug 11, 2023	SELL	$28.53 - $39.55 $3.63 Million - $5.03 Million	-127,293 Reduced 23.76%	408,519 $13.4 Million
Q1 2023 May 12, 2023	BUY	$29.51 - $46.65 $15.8 Million - $25 Million	535,812 New	535,812 $18 Million

125

53M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $105M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.